New patient mobility allows piecemeal capital investments around the EU
This article was originally published in Clinica
Patient mobility comes at a high cost to the smaller countries of the EU, which send their patients to neighbouring countries for treatment due to the lack of availability of services or technology at home. It has the effect of diverting healthcare funds - often to countries with high fees - and this inevitably delays the introduction of new technologies and treatments in the home country.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.